Andrew Armstrong, MD, of Duke University Cancer Center, discusses new guidelines from Prostate Cancer Working Group 4, including the main drivers that necessitated the update, and how the new recommendations incorporate emerging biomarkers and data.
Dr. Armstrong also elaborates on new imaging-specific rPFS criteria and updated intervals for imaging, and what he believes are the most critical areas that need a coordinated effort to support the next generation of prostate cancer trials.
High-dose chemotherapy appears to provide greater benefit than conventional-dose chemotherapy, particularly when TF is high.
Researchers aimed to determine the value of plasma and urine ctDNA in localized, locally advanced, and metastatic UC.
Drs. Tawagi and Armstrong recap promising belzutifan data in RCC and early cabo activity in refractory germ cell tumors.
Drs. Tawagi and Armstrong review prostate trials on radium combos, PARP strategies, and optimal ADT duration.
This analysis marks the longest phase 3 follow-up of a first-line checkpoint inhibitor combination for aRCC.
Dr. Yousef Zakharia discusses a study on utilizing ctDNA as a biomarker of response to EV/pembro in MIBC.
Dr. Matthew B. Rettig explains factors guiding the choice between docetaxel rechallenge and cabazitaxel in mCRPC.
Dr. Matthew B. Rettig provides an overview of his trial that evaluated treatment rechallenge with docetaxel in mCPRC.
The panel highlights that neoadjuvant therapy for RCC is promising while emphasizing the need for modern trial designs.
Dr. Joaquim Bellmunt gives an overview of the IMvigor011 study on ctDNA monitoring to guide adjuvant immunotherapy in MIBC.
A multidisciplinary team of clinicians and scientists—under the auspices of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center—is redefining what is possible for patients with both muscle-invasive and non–muscle-invasive bladder cancer.
Leveraging breakthroughs in genomic profiling, molecular imaging, and immunotherapy, UCSF is moving beyond traditional treatment paradigms and toward a model grounded in precision medicine.
Join the largest community of verified healthcare professionals working together, safely and securely, to improve patient outcomes.
Figure 1 Member Post
Figure 1 Member Post
Figure 1 Member Post
Rahul Aggarwal, MD, describes the long-term follow-up results of the PRESTO study as presented at ESMO Congress 2025.
Dr. Evan Kovac speaks about his pioneering work with extended reality display technology in urologic surgery and education.
Dr. Zlotta discusses the current state and future of bladder-sparing therapy in MIBC, including how to best select patients.
Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.
Drs. Saji and Lebastchi explore focal therapy, covering its historical evolution, techniques, and energy modalities.
Curated clinical content based on conditions, therapies, and technologies
Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD
Live meeting highlights
Drs. Tawagi and Armstrong recap promising belzutifan data in RCC and early cabo activity in refractory germ cell tumors.
Drs. Tawagi and Armstrong review prostate trials on radium combos, PARP strategies, and optimal ADT duration.
Dr. Yousef Zakharia discusses a study on utilizing ctDNA as a biomarker of response to EV/pembro in MIBC.
180 Mount Airy Rd., Suite 205
Basking Ridge, NJ 07920
© 2026 Formedics, LLC. All Rights Reserved.
